Description of the medicine: Solutizon (Soluthizonum)
Sodium methylene sulfonate p-aminobenzalthiosemicarbazone monohydrate.
Synonym: Tibon soluble.
The crystalline powder is yellowish-green in color. It is difficult and slowly soluble in water, practically insoluble in alcohol.
Solutizon has, like thioacetazone (tibone), bacteriostatic activity against tuberculosis mycobacteria. Solubility in water allows the use of the drug for inhalation in the form of an aerosol, for lubrication, or by intra-throat and intrabronchial administration of the solution in the treatment of tuberculosis of the upper respiratory tract, bronchi and lungs. Solutizon is especially indicated for chronic fibro-cavernous tuberculosis, when anti-TB drugs do not penetrate well from the blood through the dense fibrous wall of the cavity. The solution can also be used in the form of an aerosol or by intrabronchial administration for the preparation in surgical treatment of patients with chronic fibro-cavernous tuberculosis.
For inhalations, 2 to 3 ml of 1 to 2% solution is prescribed (for children, 1% solution); the duration of the session is 7 - 10 - 12 minutes. Treatment is carried out for 1 to 2 months, 1 to 2 times a day.
Depending on the indications, the course of treatment can be repeated.
Intratracheally injected 2 - 5 ml for the introduction of 1 - 2% solution (using a laryngeal syringe).
Solutions are prepared immediately before use under aseptic conditions in distilled water. For better dissolution, warm to + 30 C, then cool to the desired temperature. Sterilization by heating is not carried out, since the drug decomposes at high temperature.
Solutizon aerosol can be combined with the ingestion of other anti-TB drugs.
When using solutizon solutions, irritation of the respiratory tract, cough may be observed; in these cases, treatment is interrupted for several days or the concentration of the solution is reduced (from 2% to 1%). With intolerance phenomena, further inhalation of the solution of solutizon is stopped.
Inhalation of a solution of solutison is contraindicated in severe and decompensated forms of the fibro-cavernous process, cardiopulmonary insufficiency, candidiasis of the mucous membranes of the upper respiratory tract and oral cavity.
Release form: powder; 2% solution in ampoules of 2 ml in a package of 10 ampoules.
Storage: List B. In the dark place.